Several blockbusters are set to take a nosedive this year as patent losses hit Novartis, Merck & Co., Bristol-Myers Squibb and other top pharma companies.
Dickson Data has compiled a list of major drugs losing their IP protection this year, and standing at the top is Novartis’ Sandostatin LAR with $1.6 billion in annual sales. Used to treat acromegaly and severe diarrhea and flushing associated with carcinoid syndrome, the drug will quickly face generic erosion from a slew of companies, including Teva, Sun Pharma, Sagent Pharmaceuticals and Wockhardt.
Behind Sandostatin LAR is Merck’s antibiotic Cubicin, a key prize in the New Jersey pharma giant’s $9.5 billion purchase of Cubist Pharmaceuticals back in 2014. The drug currently tallies $1.17 billion in sales, according to Dickson, and is set to face cheaper rivals from Hospira, Teva and Crane Pharma, FDA records show.
Merck faces another blockbuster loss, too: Its cholesterol med Vytorin, with $1.12 billion in sales, comes in fourth place, according to Dickson. Bristol-Myers’ HIV drug Reyataz stands in third place with $1.14 billion.
Branded drugs tend to lose 90% of their sales after multiple generics make it to market, according to the firm. The copycats are typically 80 to 85% cheaper than the branded originals.
Although not a blockbuster like others on the list, Eli Lilly’s ADHD med Strattera rounds out the top five drugs facing a patent expiration, Dickson found, with annual sales just shy of $700 million. Zydus, Aurobindo, Sun Pharma and Mylan are among the companies seeking to grab a piece of that drug’s annual haul.
Merck’s antibiotic Invanz and antifungal med Cancidas are also set to lose patent protection for the New Jersey pharma giant; all told, the drugmaker has four meds totaling $3.8 billion in sales—10% of its total haul—susceptible to generics this year.
By Eric Sagonowsky
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.